2013 International Meeting on the Molecular Biology of Hepatitis B Viruses

2013年乙型肝炎病毒分子生物学国际会议

• 批准号: 8526887
• 负责人: SHUPING TONG
• 金额: $ 1万
• 依托单位: HEPATITIS B FOUNDATION
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-09-01 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8526887
• 关键词: Animal Model; Antiviral Agents; Antiviral Therapy; Applications Grants; Area; Authorization documentation; Basic Science; Biochemistry; Biology; Cellular biology; Cessation of life; China; Chinese People; Chronic Hepatitis B; Cirrhosis; Collaborations; Communities; Complex; DNA biosynthesis; Development; Diabetes Mellitus; Digestive System Disorders; Disease; Doctor of Philosophy; Educational workshop; Equilibrium; Europe; Event; Family; Feedback; Fostering; Foundations; Fund Raising; Funding; Future; Genetic Transcription; Grant; Growth; HBV Genotype; Hepatitis B; Hepatitis B Virus; Hepatitis C; Hepatitis C virus; Hepatitis Delta Virus; Home environment; Immune response; Immunology; Individual; Infection; Institutes; International; Investigation; Joints; Kidney Diseases; Lead; Life; Liver Failure; Minority; Molecular Biology; Morphogenesis; Mothers; National Institute of Allergy and Infectious Disease; Nature; Oral; Pathogenesis; Perinatal; Population; Postdoctoral Fellow; Primary carcinoma of the liver cells; Proteins; Public Health; Relative (related person); Research; Research Personnel; Rice; Schedule; Scientist; Senior Scientist; Series; Speech; Students; System; Time; Translations; Travel; Underrepresented Minority; United States National Institutes of Health; Universities; Vaccines; Viral; Virus; Virus Diseases; Virus Receptors; Work; carcinogenesis; cost; experience; graduate student; medical schools; meetings; mouse model; mutant; pathogen; posters; prophylactic; public health relevance; receptor; reconstitution; trafficking; transmission process; unpublished works; virology

DESCRIPTION (provided by applicant): This proposal is a request for funding to support the travel expenses for young scientists to attend the 2013 International Meeting on the Molecular Biology of Hepatitis B Viruses, scheduled for Oct. 20 - 23 at Shanghai Medical College, Fudan University, Shanghai, China. This meeting, which has been held consecutively since 1985, is the only forum that gathers the international community of researchers focusing on the hepatitis B virus (HBV) and the closely associated hepatitis delta virus (HDV). Approximately a quarter of the world's population has been infected by HBV, and 350 million remain chronically infected of which 15 million are co- infected with HDV. As a result, nearly a million people die annually from complications of chronic HBV infection including liver failure, cirrhosis, and hepatocellular carcinoma. Current antiviral therapies are costly and ineffective. New HBV infections continue to arise despite the prophylactic vaccine, due to both underutilization of the vaccine and difficulty n interrupting perinatal transmission from infected mothers. It is therefore imperative that basic research on HBV continues and latest progress in the field is discussed and disseminated in a timely manner. A unique feature of the 2013 meeting is that it will be held for the first time in China, home to one-third of chronic hepatitis B carriers worldwide. It is anticipated that the meeting will promote lively scientific exchange between Chinese researchers and experts from the outside world and lead to fruitful collaborations in the near future. Besides the 10 oral sessions and two poster sessions, the workshop for the 2013 meeting will debate how chronic HBV infection causes hepatocellular carcinoma and evaluate the impact of antiviral therapy. The keynote speech by William Mason, a respected leader in the HBV field, will summarize major accomplishments of the field and point out matters requiring further investigation. One such area is the nature of the HBV receptor and early events in HBV lifecycle. In this regard Dr. Charles Rice's keynote speech will highlight the recent progress in identifying receptors for hepatitis C virus (HCV) and reconstituting a mouse model of HCV infection. As in the past, great effort has been made to minimize the cost of the meeting. Since 2005, the Hepatitis B Foundation has made a strong commitment to support this meeting by providing a permanent home for the meeting and making its staff available for publicizing the meeting, especially to universities with large numbers of underrepresented minorities. In order to allow the participation of junior and minority investigators, support from the NIH to help defray the meeting costs is requested.

描述（由申请人提供）：该提案是一项要求资助的要求，以支持年轻科学家参加2013年2013年国际丙型肝炎病毒分子生物学会议，该会议定于10月20日至23日在中国上海法丹大学上海医学院举行。自1985年以来，这次会议一直是连续举行的，是唯一聚集着专注于丙型肝炎病毒（HBV）和密切相关的肝炎Delta病毒（HDV）的国际研究人员社会的论坛。大约四分之一的世界人口已被HBV感染，而3.5亿仍感染了3.5亿，其中1500万感染了HDV。结果，近一百万人每年死于慢性HBV感染并发症，包括肝衰竭，肝硬化和肝细胞癌。当前的抗病毒疗法是昂贵且无效的。尽管采用预防性疫苗，但由于疫苗不足以及难以中断受感染的母亲的围产期传播而导致的新型HBV感染仍在继续产生。因此，必须及时讨论和传播有关HBV的基础研究，并及时讨论和传播该领域的最新进展。 2013年会议的一个独特特征是，它将首次在中国举行，这是全球慢性乙型肝炎载体的三分之一。可以预料，这次会议将促进中国研究人员与外界专家之间的生动科学交流，并在不久的将来带来富有成果的合作。除了10次口腔会议和两个海报会议外，2013年会议的研讨会还将辩论慢性HBV感染如何引起肝细胞癌并评估抗病毒疗法的影响。 HBV领域受人尊敬的领导人威廉·梅森（William Mason）的主题演讲将总结该领域的主要成就，并指出需要进一步调查的事项。这样一个领域是HBV受体的性质和HBV生命周期中的早期事件。在这方面，查尔斯·赖斯（Charles Rice）博士的主题演讲将强调识别丙型肝炎病毒（HCV）受体的最新进展，并重建了HCV感染的小鼠模型。与过去一样，已经做出了巨大的努力来最大程度地减少会议的成本。自2005年以来，丙型肝炎基金会通过为会议提供永久住所并使其员工宣传会议，尤其是对大量代表性不足的少数群体的大学，致力于支持这次会议。为了允许初级和少数民族调查员的参与，NIH的支持以帮助会议 要求成本。